All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000046-21 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subje... | 2007-07-17 | due-trials |
| Reported results | 2004-000145-38 | A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remittin... | 2006-11-03 | due-trials |
| Completed, but no date, and reported results | 2004-000326-70 | A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperido... | bad-data | |
| Reported results | 2004-000617-19 | A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer | 2008-12-18 | due-trials |
| Reported results | 2004-000730-37 | A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and ... | 2006-10-03 | due-trials |
| Completed, but no date, and reported results | 2004-000830-35 | Maintenance of the clinical response with long-acting injectable Risperidone in patients with Schizophrenia or schizoaffective disorders | bad-data | |
| Reported results | 2004-000870-29 | CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness | 2007-12-18 | due-trials |
| Reported results | 2004-001178-13 | An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have... | 2006-10-18 | due-trials |
| Reported results | 2004-001201-10 | Comparison of transdermal fentanyl PCA and IV morphine PCA in the management of post-operative pain control. | 2005-04-24 | due-trials |
| Reported results | 2004-001719-77 | A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older. | 2007-12-27 | due-trials |
| Reported results | 2004-001730-17 | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF CEFTOBIPROLE VERSUS LINEZOLID PLUS CEFTAZIDIME IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA | 2007-05-29 | due-trials |
| Reported results | 2004-001842-34 | A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | 2014-06-05 | due-trials |
| Reported results | 2004-001989-41 | An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal... | 2011-11-08 | due-trials |
| Reported results | 2004-002069-19 | A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures | 2010-06-17 | due-trials |
| Reported results | 2004-002130-18 | A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbazine... | 2009-02-06 | due-trials |
| Reported results | 2004-002694-22 | A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o... | 2007-10-24 | due-trials |
| Reported results | 2004-002700-16 | A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation | 2007-08-17 | due-trials |
| Reported results | 2004-002815-10 | Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive ... | 2009-12-11 | due-trials |
| Reported results | 2004-003295-10 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF 945; Monoclonal Antibody, Administered Subcutaneously, in Methotrexatena ve Subjects with Activ... | 2012-06-06 | due-trials |
| Reported results | 2004-003296-36 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthriti... | 2012-05-17 | due-trials |
| Reported results | 2004-003298-10 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis | 2012-01-13 | due-trials |
| Reported results | 2004-003299-12 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondyli... | 2012-01-18 | due-trials |
| Reported results | 2004-003781-14 | A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, wi... | 2008-02-21 | due-trials |
| Reported results | 2004-004162-33 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine | 2006-02-06 | due-trials |
| Reported results Terminated | 2004-004648-29 | A Multicenter, Open-label, Phase 2 Study of VELCADE bortezomib for Injection in Previously treated Patients with Stage IIIB an IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveol... | 2008-07-16 | due-trials |
| Reported results | 2004-005187-24 | Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subje... | 2008-04-30 | due-trials |
| Reported results | 2004-005213-11 | A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acut... | 2006-06-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2005-001234-32 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age | 2006-11-29 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2005-001338-33 | A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurren... | 2007-11-05 | bad-data |
| Exempt, with results | 2005-001339-31 | Estudio abierto, aleatorizado, multicéntrico con extensión abierta para evaluar la farmacocinética y seguridad de la solución oral líquida y de la formulación dispersable de topiramato como terapia a... | 2007-10-31 | not-yet-due |
| No trial status on register, and reported results | 2005-001438-34 | A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Efficacy of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and To... | bad-data | |
| Reported results | 2005-001742-16 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis... | 2012-05-22 | due-trials |
| Reported results | 2005-001845-40 | A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia | 2007-01-25 | due-trials |
| Reported results | 2005-002301-23 | A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections | 2007-01-31 | due-trials |
| Reported results | 2005-002304-41 | Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode | 2009-12-29 | due-trials |
| Reported results | 2005-002486-36 | A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. | 2012-05-08 | due-trials |
| Reported results | 2005-002979-33 | Estudio de la eficacia y seguridad de risperidona en el tratamiento de adolescentes con esquizofrenia: Estudio abierto de seis meses. | 2006-12-20 | due-trials |
| Reported results | 2005-003232-21 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis... | 2009-09-26 | due-trials |
| Reported results | 2005-003357-27 | A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Can... | 2008-01-01 | due-trials |
| Reported results | 2005-003525-92 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Trial of CNTO 1275, a Fully Human Anti IL 12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Ar... | 2007-12-20 | due-trials |
| Reported results | 2005-003530-17 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis | 2011-10-07 | due-trials |
| Exempt, with results Terminated | 2005-003843-30 | Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple Myeloma | 2006-08-14 | not-yet-due |
| Completed, but no date, and reported results | 2005-003902-27 | Clinical trial on induction of remission with bortezomib (Vel), cyclophosphamide (C) and dexamethasone (D) in patients until the age of 60 with untreated multiple myeloma and planned high dosage chemo... | bad-data | |
| Reported results | 2005-003949-14 | Pilot study of bortezomib under rituximab standard therapy in patients with relapsed or refractory follicular lymphoma and at least 2 prior therapies | 2008-12-01 | due-trials |
| Reported results | 2005-004037-18 | An Open Label, Multicenter Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder | 2008-07-10 | due-trials |
| Reported results | 2005-004087-24 | Global assessment of treatment with IONSYS and its handling by patients, doctors and nursing staff in the management of acute moderate to severe post-surgery pain in hospitalised patients. | 2008-09-26 | due-trials |
| Reported results | 2005-004174-24 | A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | 2007-05-17 | due-trials |
| Reported results | 2005-004383-23 | Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly aderant subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperidone m... | 2009-03-31 | due-trials |
| Reported results | 2005-004621-25 | Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta | 2008-03-14 | due-trials |
| Reported results | 2005-004947-73 | Bortezomib as consolidation therapy in patients aged 61-75 years with multiple myeloma | 2013-05-24 | due-trials |
| Reported results | 2005-004948-31 | Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma | 2013-05-23 | due-trials |
| Exempt, with results | 2005-005343-26 | Open-Label Study to Evaluate the Safety and Pharmacokinetics of Single-and Multiple-Dose Extended-Release OROS Paliperidone in Pediatric Subjects (>/= 10 to </= 17 Years of Age) with Schizophrenia, Sc... | 2006-10-06 | not-yet-due |
| Reported results | 2005-005345-19 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stab... | 2007-10-01 | due-trials |
| Reported results | 2005-005777-30 | A Randomized, Open Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular Non-Hodgkin s B-cell Lymphoma | 2010-07-02 | due-trials |
| Reported results | 2005-005812-25 | A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexibly... | 2007-11-16 | due-trials |
| Reported results | 2005-005819-26 | A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE | 2010-02-02 | due-trials |
| Reported results | 2005-006111-47 | A double-blind, randomised, parallel group pilot study to compare macrogol 3350 + electrolytes versus placebo in the overnight relief of constipation | 2006-07-10 | due-trials |
| Reported results | 2006-000410-20 | A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects with Moderately to Severely Active Ulcerative... | 2010-06-24 | due-trials |
| Reported results | 2006-000835-84 | Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia | 2007-07-19 | due-trials |
| Completed, but no date, and reported results | 2006-000846-38 | A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acu... | bad-data | |
| Reported results | 2006-000914-19 | A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ... | 2009-09-10 | due-trials |
| Reported results | 2006-001475-38 | A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS. | 2007-02-27 | due-trials |
| Reported results | 2006-001490-15 | A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the tr... | 2009-04-13 | due-trials |
| Reported results | 2006-001671-38 | A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer ... | 2008-11-20 | due-trials |
| Reported results | 2006-001709-27 | A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® when added to Adriamycin-Dexamethasone Treatment versus Vincristine-Adriamycin-Dexa... | 2008-02-28 | due-trials |
| Reported results | 2006-001897-26 | A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma | 2010-03-03 | due-trials |
| Reported results | 2006-001904-36 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refra... | 2019-09-24 | due-trials |
| Completed, but no date, and reported results | 2006-002499-16 | Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. | bad-data | |
| Completed, but no date, and reported results | 2006-003278-93 | Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthri... | bad-data | |
| Exempt | 2006-003359-19 | An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome | not-yet-due | |
| Reported results | 2006-003397-94 | A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately ... | 2009-05-22 | due-trials |
| Reported results | 2006-003398-28 | A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately... | 2010-11-29 | due-trials |
| Reported results | 2006-003399-37 | A Phase 3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately... | 2015-02-12 | due-trials |
| Reported results | 2006-003431-78 | A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE®) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary disease (COPD) | 2009-12-15 | due-trials |
| Reported results | 2006-003444-30 | A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | 2009-01-15 | due-trials |
| Reported results | 2006-003482-14 | A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects with Chronic Pain | 2018-07-28 | due-trials |
| Reported results | 2006-003560-62 | A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizop... | 2009-07-01 | due-trials |
| Reported results | 2006-003659-19 | A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiety i... | 2007-02-02 | due-trials |
| Reported results | 2006-003839-68 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset S... | 2010-11-05 | due-trials |
| Reported results | 2006-003941-17 | A randomized,double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset se... | 2007-10-12 | due-trials |
| Reported results | 2006-003983-73 | A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Thera... | 2008-03-10 | due-trials |
| Reported results | 2006-004015-21 | Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis | 2007-03-15 | due-trials |
| Reported results | 2006-004265-34 | An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia | 2020-03-04 | due-trials |
| Reported results | 2006-004513-18 | A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treat... | 2007-12-22 | due-trials |
| Reported results | 2006-004514-40 | A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects ... | 2007-08-22 | due-trials |
| Reported results | 2006-005734-20 | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder | 2008-06-27 | due-trials |
| Reported results | 2006-005766-39 | A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subje... | 2010-02-02 | due-trials |
| Reported results | 2006-006050-10 | A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Mu... | 2013-10-16 | due-trials |
| Reported results | 2006-006434-17 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmita... | 2008-03-24 | due-trials |
| Reported results | 2006-006437-40 | A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination the... | 2011-01-13 | due-trials |
| Reported results Terminated | 2006-006513-33 | A double-blind, randomized, parallel group comparison of Nizoral® cream (F012), ketoconazole 2% cream (F126) and placebo (F000) in the treatment of interdigital Tinea Pedis. | 2009-02-26 | due-trials |
| Reported results | 2006-006642-34 | Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia | 2009-05-14 | due-trials |
| Reported results | 2006-006755-12 | An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001 | 2012-09-04 | due-trials |
| Reported results | 2006-006772-38 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects | 2008-06-30 | due-trials |
| Reported results | 2006-006911-60 | Randomised, double-blind, placebo-controlled, parallel-group trial to investigate the analgesic effect of OROS hydromorphone hydrochloride in comparison with placebo in subjects with moderate to sever... | 2008-11-24 | due-trials |
| Reported results | 2006-006967-22 | A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia | 2009-04-07 | due-trials |
| Reported results | 2007-000031-26 | A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110 | 2008-09-12 | due-trials |
| Reported results | 2007-000280-17 | An Open Label Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-17299425 in Patients with Traumatic Brain Injury. | 2008-08-28 | due-trials |
| Trial is outside EEC, and reported results | 2007-000576-16 | A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophren... | bad-data | |
| Trial is partly outside EEC, and reported results | 2007-000577-38 | A 2 Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia | 2013-07-16 | bad-data |
| Reported results | 2007-001117-42 | A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventil... | 2008-11-05 | due-trials |
| Reported results | 2007-001462-33 | A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone and... | 2011-08-02 | due-trials |
| Reported results | 2007-001670-84 | Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure | 2011-03-15 | due-trials |
| Completed, but no date, and reported results | 2007-001801-99 | An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure | bad-data | |
| Reported results | 2007-001985-34 | A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR* in subjects with moderate to severe chronic maligna... | 2009-05-05 | due-trials |
| Reported results | 2007-002111-82 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in A... | 2009-04-02 | due-trials |
| Reported results | 2007-002780-27 | A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease | 2012-05-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-002929-78 | A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in S... | 2010-05-09 | bad-data |
| Reported results | 2007-003288-36 | A Phase 4, Multicenter, Open-Label, Assessor-blinded, Switch Study o fthe Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to E... | 2010-06-07 | due-trials |
| Completed, but no date, and reported results | 2007-003464-22 | A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects With ... | bad-data | |
| Exempt, with results | 2007-003783-22 | Daratumumab (HuMax-CD38) safety study in multiple myeloma – Open label, dose-escalation followed by open label, single-arm study | 2017-04-03 | not-yet-due |
| Reported results | 2007-004151-11 | A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab | 2011-09-13 | due-trials |
| Reported results | 2007-004254-93 | A Non-Randomized, Within Subject Placebo-Controlled Exploratory Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal EEG Response in Subjects with Photosensitive Epilepsy | 2008-07-21 | due-trials |
| Reported results | 2007-004482-18 | A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone. | 2008-07-18 | due-trials |
| Reported results | 2007-004646-33 | A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem in the Treatment of Subjects with Ventilator-Associated P... | 2011-06-15 | due-trials |
| Reported results | 2007-005633-10 | A Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals where Pseudomonas aeruginosa may be a Prevalent Pathogen. | 2008-11-25 | due-trials |
| Reported results | 2007-005669-37 | A Randomised Open Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincris... | 2017-06-30 | due-trials |
| Reported results | 2007-005837-13 | A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetax... | 2012-10-11 | due-trials |
| Reported results | 2007-006175-36 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects | 2008-10-08 | due-trials |
| Completed, but no date, and reported results | 2007-006603-20 | A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutane... | bad-data | |
| Reported results | 2007-006693-28 | A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally adminis... | 2009-01-23 | due-trials |
| Reported results | 2007-007083-22 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizoph... | 2010-02-01 | due-trials |
| Ongoing | 2007-007520-17 | A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocy... | not-yet-due | |
| Reported results | 2007-007669-20 | A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable S... | 2009-01-12 | due-trials |
| Exempt, with results | 2008-000451-97 | A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Years old, inclusive | not-yet-due | |
| Reported results | 2008-000452-27 | A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Months old, Inclusive | 2012-02-29 | due-trials |
| Reported results Terminated | 2008-000529-20 | Comparison of Ionsys® and routine care with morphine IV PCA in the management of early post-operative mobilisation, ability to mobilise and in time to Fitness For Discharge (FFD) | 2008-11-19 | due-trials |
| Reported results | 2008-000649-77 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Cr... | 2010-12-09 | due-trials |
| Reported results | 2008-000952-28 | An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma | 2011-03-21 | due-trials |
| Ongoing | 2008-001173-14 | An Open-Label Evaluation of Safety of the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] for Management of Acute Post- Operative Pain in Pediatric Patients | not-yet-due | |
| Reported results | 2008-001281-86 | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Sub... | 2012-01-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-001696-30 | A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral naive HIV1 infected adolescents and ch... | bad-data | |
| Completed, but no date, and reported results Terminated | 2008-002074-35 | Clinical outcome study in postoperative pain management to demonstrate the efficacy and safety of IONSYS (fentanyl ITS Iontophoretic Transdermal System) in daily clinical practice and to assess its co... | bad-data | |
| Reported results | 2008-002210-22 | An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-00... | 2012-08-02 | due-trials |
| Reported results | 2008-002247-16 | A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate... | 2014-05-10 | due-trials |
| Reported results | 2008-002383-34 | A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple co... | 2011-04-15 | due-trials |
| Completed, but no date, and reported results | 2008-002384-13 | Efficacy and Tolerability of Flexible Doses of Paliperidone ER in Symptomatic Subjects with Schizophrenia with duration of illness < 10 years | bad-data | |
| Reported results | 2008-002498-11 | PILOT STUDY ON USAGE PATTERNS OF A NOVEL NICOTINE REPLACEMENT THERAPY - A MULTI-CENTER, OPEN, 3-WEEK RANDOMIZED LOW INTERVENTION STUDY OF TWO DIFFERENT DIRECTIONS FOR USE IN SMOKERS MOTIVATED TO QUIT | 2008-12-05 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-002653-21 | Number of Doses and Time to Onset Of Pain Relief (Analgesic Effect) Using the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] | bad-data | |
| Reported results | 2008-002708-25 | A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome | 2011-12-20 | due-trials |
| Reported results Terminated | 2008-002723-85 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Interme... | 2009-12-18 | due-trials |
| Reported results | 2008-003213-27 | Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma | 2013-01-08 | due-trials |
| Reported results Terminated | 2008-003340-11 | The “therapeutic window” of the "atypical” antipsychotic paliperidone ER - A Positron Emission Tomography study with [18F]fallypride as the radiotracer | 2010-01-13 | due-trials |
| Reported results | 2008-004264-39 | A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease | 2014-04-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2008-004837-54 | A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulati... | 2011-01-25 | bad-data |
| Reported results | 2008-004847-12 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed-Release Rabeprazole in 1- to 11-Month-Old Pediatric Subject... | 2011-11-16 | due-trials |
| Reported results | 2008-005098-37 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset... | 2010-08-31 | due-trials |
| Exempt, with results | 2008-005180-33 | A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid... | 2011-11-04 | not-yet-due |
| Ongoing | 2008-005237-30 | A Multicenter, Prospective, Long-term Registry of Pediatric Patients with Crohn's Disease | not-yet-due | |
| Reported results | 2008-006064-11 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Metho... | 2013-02-08 | due-trials |
| Reported results | 2008-006845-13 | Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit. | 2010-06-16 | due-trials |
| Reported results | 2008-007157-12 | A Randomized, Open label, Phase 2 Study of CNTO 328 (Anti IL 6 Monoclonal Antibody) and VELCADE Melphalan Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreate... | 2013-04-11 | due-trials |
| Reported results | 2008-007478-39 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Trau... | 2010-12-23 | due-trials |
| Reported results | 2008-007687-41 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset... | 2009-11-23 | due-trials |
| Reported results | 2008-007688-17 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset... | 2010-08-31 | due-trials |
| Reported results | 2008-007690-21 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Follo... | 2015-01-19 | due-trials |
| Reported results Terminated | 2008-007800-27 | A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia Wh... | 2010-02-05 | due-trials |
| Reported results | 2008-008004-41 | A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prosta... | 2017-05-25 | due-trials |
| Reported results | 2008-008171-34 | AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT) | 2011-08-17 | due-trials |
| Reported results | 2008-008444-25 | A Phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB. | 2013-01-24 | due-trials |
| Reported results | 2008-008655-42 | A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination... | 2011-01-12 | due-trials |
| Reported results | 2008-008753-33 | A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase | 2010-12-09 | due-trials |
| Reported results | 2009-009320-36 | A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared With G... | 2013-01-30 | due-trials |
| Reported results Terminated | 2009-009856-19 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or ... | 2010-12-23 | due-trials |
| Completed, but no date, and reported results | 2009-009857-17 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately ... | bad-data | |
| Reported results | 2009-010582-23 | A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (EN... | 2013-10-03 | due-trials |
| Reported results | 2009-010714-30 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoi... | 2012-08-17 | due-trials |
| Reported results | 2009-011250-17 | An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti- CCL2 Monoclonal Antibody) for the Treatment of Subjects with Recurrent Ovarian Cancer | 2010-07-14 | due-trials |
| Reported results | 2009-011251-48 | An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer | 2011-07-06 | due-trials |
| Reported results | 2009-011309-18 | A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care | 2012-08-31 | due-trials |
| Completed, but no date, and reported results | 2009-011343-39 | Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders | bad-data | |
| Reported results | 2009-012003-26 | Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs | 2011-07-26 | due-trials |
| Reported results | 2009-012118-27 | A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biop... | 2010-10-29 | due-trials |
| Reported results | 2009-012140-16 | A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus | 2017-02-22 | due-trials |
| Reported results | 2009-012264-14 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo controlled trial of Ustekinumab, a Fully Human anti-IL 12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psori... | 2013-05-30 | due-trials |
| Reported results | 2009-012265-60 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psori... | 2012-11-15 | due-trials |
| Reported results | 2009-012280-34 | A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincr... | 2013-07-23 | due-trials |
| Reported results | 2009-012380-34 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje... | 2017-03-01 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-012444-16 | A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults with Persistent Asthma | bad-data | |
| Reported results | 2009-012613-21 | An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21... | 2012-05-16 | due-trials |
| Reported results | 2009-012748-17 | A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disea... | 2012-06-05 | due-trials |
| Reported results | 2009-013616-12 | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfu... | 2011-09-02 | due-trials |
| Reported results | 2009-013689-18 | ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA | 2011-06-28 | due-trials |
| Reported results | 2009-013929-42 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects with Heart Failure ... | 2011-11-21 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-014368-20 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type ... | 2014-01-04 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-014387-20 | An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age | 2012-04-30 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-014811-11 | A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophre... | 2012-06-11 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-015019-42 | A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis (JI... | 2014-06-27 | bad-data |
| Reported results | 2009-015629-35 | Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression | 2011-12-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-015864-32 | A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infec... | 2013-08-05 | bad-data |
| Reported results | 2009-015870-36 | Nicotine pharmacodynamics with a new oral nicotine replacement product and NiQuitin Lozenge. A study in healthy smokers. | 2010-05-19 | due-trials |
| Reported results | 2009-015883-32 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Multicenter Study with a 26 Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 as Monotherapy in... | 2012-03-20 | due-trials |
| Reported results | 2009-015885-75 | A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants with a Corrected Age of Less than 44 Weeks with a... | 2012-01-11 | due-trials |
| Completed, but no date Terminated | 2009-015931-33 | An open label, prospective, multicenter, single-arm clinical trial to investigate the safety and the analgesic effectiveness of a low dose (4 mg) OROS hydromorphone hydrochloride as starting dose in... | bad-data | |
| Trial is partly outside EEC, and reported results | 2009-015953-18 | A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infectio... | 2013-08-05 | bad-data |
| Trial is partly outside EEC, and reported results | 2009-016069-27 | A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | 2013-08-05 | bad-data |
| Reported results | 2009-016366-88 | A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 D... | 2012-04-17 | due-trials |
| Reported results | 2009-016525-34 | A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Si... | 2012-05-29 | due-trials |
| Reported results | 2009-017013-29 | Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1 | 2017-11-23 | due-trials |
| Reported results | 2009-017136-40 | A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the T... | 2012-08-02 | due-trials |
| Reported results | 2009-017237-22 | A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract... | 2011-09-15 | due-trials |
| Reported results | 2009-017271-17 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder | 2013-10-22 | due-trials |
| Reported results | 2009-018022-30 | A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully tre... | 2013-11-29 | due-trials |
| Reported results | 2009-018070-64 | A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflo... | 2012-07-03 | due-trials |
| Reported results | 2009-018109-29 | A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROG... | 2012-02-15 | due-trials |
| Reported results | 2010-018411-15 | A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Su... | 2013-05-23 | due-trials |
| Reported results | 2010-018431-18 | Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgic... | 2014-12-12 | due-trials |
| Reported results | 2010-019843-20 | A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) infection | 2016-01-05 | due-trials |
| Reported results | 2010-019881-96 | A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. VEHICLE IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECI... | 2011-08-30 | due-trials |
| Reported results | 2010-020053-14 | A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabete... | 2012-03-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-020380-20 | Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years | 2013-03-23 | bad-data |
| Reported results | 2010-020444-36 | A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2... | 2013-01-29 | due-trials |
| Reported results | 2010-020968-38 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lupus ... | 2013-09-24 | due-trials |
| Reported results | 2010-021113-23 | ""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterfe... | 2013-02-04 | due-trials |
| Reported results | 2010-021125-12 | Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB | 2016-12-01 | due-trials |
| Reported results | 2010-021174-11 | A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2... | 2013-02-05 | due-trials |
| Reported results | 2010-021209-18 | "Ensayo abierto con TMC278 25 mg al día en combinación con una pauta de base con dos inhibidores de la transcriptasa inversa nucleosídicos/nucleotídicos en pacientes infectados por el VIH-1 que partic... | 2020-02-28 | due-trials |
| Reported results | 2010-021337-31 | A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFN?-2a (Pegasys)® and ribavirin (Copegus)® triple therapy in chronic hepatitis C genotype-1 infected s... | 2013-08-28 | due-trials |
| Reported results | 2010-021425-13 | An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy | 2015-10-19 | due-trials |
| Reported results | 2010-021628-84 | A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-na�ve subjects with genoty... | 2012-11-28 | due-trials |
| Reported results | 2010-022242-24 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active R... | 2016-12-06 | due-trials |
| Reported results | 2010-022243-38 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active ... | 2016-01-12 | due-trials |
| Reported results | 2010-022437-28 | A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model | 2011-06-06 | due-trials |
| Reported results | 2010-022758-18 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ... | 2013-07-16 | due-trials |
| Reported results | 2010-022759-42 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ... | 2014-10-28 | due-trials |
| Reported results | 2010-022760-12 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severel... | 2019-10-01 | due-trials |
| Reported results | 2010-022837-27 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | 2017-03-01 | due-trials |
| Reported results | 2010-022884-36 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate 1 Risk Myelodysplastic Syndromes Uno studi... | 2016-01-07 | due-trials |
| Reported results | 2010-023268-42 | NICOTINE PHARMACODYNAMICS WITH A NEW ORAL NICOTINE REPLACEMENT PRODUCT AND NICOTINE GUM 4 MG. A STUDY IN HEALTHY SMOKERS. | 2011-08-25 | due-trials |
| Reported results | 2010-023369-23 | FIRST-IN-PATIENT STUDY TO ASSESS THE SAFETY AND TOLERABILITY AND TO EXPLORE THE POTENTIAL THERAPEUTIC EFFICACY OF A NOVEL GLUTAMATE MODULATOR AS MONOTHERAPY AND AS ADD-ON THERAPY IN PATIENTS WITH SCHI... | 2012-12-05 | due-trials |
| Reported results | 2010-023532-16 | An open-label study to evaluate the safety, tolerability and pharmacokinetics of etravirine (ETR) in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infecte... | 2013-11-11 | due-trials |
| Reported results | 2010-023669-23 | Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhos... | 2014-05-30 | due-trials |
| Reported results | 2010-024256-28 | A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Di... | 2012-04-20 | due-trials |
| Reported results | 2011-000261-12 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Pro... | 2012-09-13 | due-trials |
| Reported results | 2011-000400-17 | A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination T... | 2014-12-02 | due-trials |
| Reported results | 2011-000416-25 | A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 stu... | 2015-03-31 | due-trials |
| Reported results | 2011-000554-31 | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects with Primary Biliary Cirrhosis Who had an Inad... | 2013-06-28 | due-trials |
| Reported results | 2011-000621-80 | Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) plus Prednisone/ Prednisolone with or without Exemestane in Postmenopausal Women with ER+ Metastatic Breast Cancer Progressing after Le... | 2018-09-20 | due-trials |
| Reported results | 2011-000653-23 | A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Mycoba... | 2013-12-19 | due-trials |
| Reported results | 2011-001066-17 | A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PL... | 2013-08-05 | due-trials |
| Reported results | 2011-001076-18 | A Phase 2, Randomized, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 at Two Dose Levels in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymp... | 2016-07-22 | due-trials |
| Exempt, with results | 2011-001114-33 | An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age | 2013-07-01 | not-yet-due |
| Reported results | 2011-001122-18 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Su... | 2014-05-05 | due-trials |
| Reported results | 2011-001180-53 | A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty... | 2014-04-28 | due-trials |
| Reported results | 2011-001303-13 | HIV postexposure prophylaxis with Darunavir/r (PEPDar) | 2013-09-28 | due-trials |
| Reported results | 2011-001635-23 | PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects Inibitore della PROTEAsi (DRV/rtv) in mono o triplice terapia in soggetti con infezione da HIV-1 virol... | 2015-03-18 | due-trials |
| Reported results | 2011-001735-22 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma | 2019-08-21 | due-trials |
| Reported results | 2011-002133-20 | A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease Who Participated in Study EL... | 2012-09-30 | due-trials |
| Exempt, with results | 2011-002796-41 | A PROOF OF CONCEPT WITH A NEW NICOTINE INHALER IN COMPARISON WITH NICOTINE INHALER 10 MG - AN EXPLORATORY STUDY IN ADULT HEALTHY SMOKERS | 2011-12-14 | not-yet-due |
| Reported results | 2011-002840-29 | A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ–38518168 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotre... | 2014-07-03 | due-trials |
| Completed, but no date, and reported results Terminated | 2011-002849-36 | A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotre... | bad-data | |
| Reported results | 2011-003593-85 | Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis... | 2014-08-26 | due-trials |
| Reported results | 2011-004097-29 | An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatme... | 2014-02-20 | due-trials |
| Reported results | 2011-004529-28 | A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Th... | 2013-03-25 | due-trials |
| Reported results | 2011-004676-11 | A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia | 2014-04-04 | due-trials |
| Reported results | 2011-004724-35 | Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects Studio d... | 2014-07-24 | due-trials |
| Reported results | 2011-004795-11 | A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy with Bortezomib (Velcade) in Patients with Multiple Myeloma in First or Second Relapse Studio random... | 2016-02-18 | due-trials |
| Reported results | 2011-004889-15 | A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia | 2018-09-19 | due-trials |
| Reported results | 2011-004928-35 | Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Genot... | 2014-06-03 | due-trials |
| Trial is outside EEC, and reported results | 2011-005159-15 | An Open-Label, Parallel-Group Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Patients 3 Months to 17 Years of Age, Inclusive | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2011-005243-28 | A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study | 2021-04-22 | bad-data |
| Reported results | 2011-005479-17 | A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques | 2014-01-06 | due-trials |
| Exempt, with results Terminated | 2011-005692-16 | An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refrac... | 2013-03-01 | not-yet-due |
| Exempt | 2011-005709-62 | An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relap... | 2012-12-06 | not-yet-due |
| Exempt, with results | 2011-005795-42 | An Open-label, Multicenter Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects with Relapsed or Refractory Hodgkin Lymphoma | 2013-08-13 | not-yet-due |
| Reported results | 2011-005808-14 | A Phase I, open-label, randomized, 3-panel, 3-way crossover trial in healthy adult subjects to assess the relative bioavailability of TMC435 following administration of 2 liquid formulations or 2 diff... | 2012-05-29 | due-trials |
| Reported results | 2011-005992-17 | A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects with Treatment-Resistant Depression | 2013-06-03 | due-trials |
| Reported results | 2011-006121-26 | A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults with Major Depressive Disorder with Anxiety Symptoms | 2013-11-25 | due-trials |
| Reported results | 2012-000600-15 | Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Re... | 2019-01-23 | due-trials |
| Reported results | 2012-000601-74 | A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Ly... | 2016-12-15 | due-trials |
| Reported results | 2012-000711-88 | A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress a... | 2015-05-31 | due-trials |
| Reported results | 2012-001176-10 | A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO13... | 2018-05-01 | due-trials |
| Reported results | 2012-001484-79 | A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation | 2014-10-29 | due-trials |
| Reported results | 2012-001491-11 | An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibr... | 2016-07-29 | due-trials |
| Reported results | 2012-001552-19 | A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects Wit... | 2020-04-30 | due-trials |
| Reported results | 2012-002555-42 | A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer wi... | 2016-01-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002940-26 | A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metas... | 2022-02-13 | bad-data |
| Reported results Terminated | 2012-002954-21 | An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycline... | 2014-07-10 | due-trials |
| Reported results | 2012-003607-36 | A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | 2015-09-28 | due-trials |
| Reported results | 2012-003629-40 | A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate T... | 2015-05-26 | due-trials |
| Ongoing | 2012-004056-11 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects Wit... | not-yet-due | |
| Reported results | 2012-004097-26 | An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma Uno studio di fase II a braccio singolo, multicentrico, in aperto su ... | 2016-05-18 | due-trials |
| Ongoing | 2012-004225-24 | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | not-yet-due | |
| Reported results | 2012-004331-23 | A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Metas... | 2018-06-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004359-35 | An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 year... | 2019-03-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2012-004366-18 | A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFα Antibody, in Pediatric Subjects with Moderately to Severely Active Ulc... | 2022-09-01 | bad-data |
| Reported results | 2012-004808-34 | A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fa... | 2018-11-16 | due-trials |
| Reported results | 2012-004905-29 | A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chronic... | 2015-08-31 | due-trials |
| Reported results | 2012-004920-39 | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma | 2015-07-22 | due-trials |
| Reported results | 2012-005184-27 | A Phase 2 Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ-49095397 (RV568) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease. | 2014-10-29 | due-trials |
| Reported results | 2012-005492-13 | A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatric f... | 2013-08-26 | due-trials |
| Reported results | 2013-000046-19 | A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjec... | 2018-05-02 | due-trials |
| Reported results | 2013-000263-88 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Ac... | 2015-12-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000390-70 | Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia. | 2017-08-28 | bad-data |
| Completed, but no date, and reported results | 2013-000752-18 | An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Protea... | bad-data | |
| Reported results | 2013-000959-40 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincr... | 2019-04-05 | due-trials |
| Reported results | 2013-001417-32 | A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheumatoi... | 2016-08-17 | due-trials |
| Reported results | 2013-001442-34 | A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS. | 2013-09-24 | due-trials |
| Reported results | 2013-001830-16 | Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of O... | 2016-09-19 | due-trials |
| Reported results | 2013-002042-36 | A Phase 2a Open-label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects with Moderately to Severely Active Ulcerative Colitis | 2016-01-29 | due-trials |
| Reported results | 2013-002535-24 | A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery | 2014-09-22 | due-trials |
| Completed, but no date, and reported results | 2013-002726-23 | Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Patients wi... | bad-data | |
| Reported results | 2013-003050-25 | A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus | 2017-02-27 | due-trials |
| Listed as ongoing, but also has a completion date | 2013-003093-27 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Either Bendamustine and Rituximab (BR) or Rituximab,... | 2023-06-21 | bad-data |
| Reported results | 2013-003548-22 | Four Week Clinical Efficacy of An Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis | 2014-07-31 | due-trials |
| Reported results | 2013-004005-11 | A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE) | 2015-09-25 | due-trials |
| Reported results | 2013-004494-28 | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe... | 2018-10-30 | due-trials |
| Reported results | 2013-004819-40 | A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects with ... | 2015-09-11 | due-trials |
| Exempt, with results | 2013-005104-33 | A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing an... | 2018-02-15 | not-yet-due |
| Trial is outside EEC, and reported results | 2013-005455-32 | Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 years of age with Type 2 D... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2013-005525-23 | Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma | 2021-09-28 | bad-data |
| Reported results | 2014-000241-74 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis | 2016-10-11 | due-trials |
| Reported results | 2014-000242-30 | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNF alpha Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis Estudi... | 2017-03-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-000255-85 | Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma | 2024-01-10 | bad-data |
| Reported results | 2014-000305-13 | Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk | 2018-05-05 | due-trials |
| Reported results | 2014-000719-15 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe ... | 2020-06-17 | due-trials |
| Reported results | 2014-000720-18 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe ... | 2020-07-01 | due-trials |
| Reported results | 2014-000721-20 | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate R... | 2016-05-24 | due-trials |
| Ongoing | 2014-001718-25 | A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemothera... | not-yet-due | |
| Reported results | 2014-002159-24 | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheimer's... | 2016-06-07 | due-trials |
| Ongoing | 2014-002272-88 | A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Mu... | not-yet-due | |
| Ongoing | 2014-002273-11 | A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High D... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2014-002408-26 | A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastati... | 2019-06-13 | bad-data |
| Trial is partly outside EEC | 2014-002471-28 | An open-label, roll-over study with rilpivirine in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) in human immunodeficiency virus ... | bad-data | |
| Reported results | 2014-002598-13 | Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoart... | 2016-10-10 | due-trials |
| Reported results | 2014-003052-31 | A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single tablet regimen versus conti... | 2020-10-13 | due-trials |
| Reported results | 2014-003224-40 | Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of O... | 2016-09-19 | due-trials |
| Trial is outside EEC | 2014-003372-23 | A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antimycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Mu... | bad-data | |
| Reported results | 2014-003413-28 | A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects | 2016-04-11 | due-trials |
| Reported results | 2014-003446-27 | A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subject... | 2015-12-23 | due-trials |
| Reported results | 2014-003679-48 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF alpha Naive Subjects With Active Radiographic ... | 2017-05-17 | due-trials |
| Reported results | 2014-003697-17 | A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis | 2017-01-17 | due-trials |
| Reported results | 2014-003879-37 | Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoart... | 2016-09-15 | due-trials |
| Reported results | 2014-004068-39 | A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combinat... | 2016-07-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2014-004250-34 | A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis ... | bad-data | |
| Reported results | 2014-004266-26 | A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Tic... | 2016-10-14 | due-trials |
| Reported results | 2014-004274-41 | A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzhei... | 2018-06-28 | due-trials |
| Reported results | 2014-004584-20 | A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subject... | 2018-02-20 | due-trials |
| Reported results | 2014-004585-22 | A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subj... | 2017-11-06 | due-trials |
| Reported results | 2014-004586-24 | A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression | 2018-02-16 | due-trials |
| Reported results | 2014-004587-38 | An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | 2017-10-30 | due-trials |
| Reported results | 2014-004588-19 | A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatm... | 2020-06-22 | due-trials |
| Reported results | 2014-005000-19 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus | 2019-03-13 | due-trials |
| Reported results | 2014-005041-41 | A Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 against Respirat... | 2015-10-02 | due-trials |
| Ongoing | 2014-005139-14 | A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma Uno studio randomizzato di fase 2 per valutare tre programmi di dosaggio di daratumumab nel mi... | not-yet-due | |
| Reported results | 2014-005206-37 | A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder | 2018-05-22 | due-trials |
| Completed, but no date, and reported results | 2014-005299-26 | An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | bad-data | |
| Reported results | 2014-005448-17 | A Phase 1, open-label, randomized, 2-panel, 3-way crossover study in healthy adult subjects to assess the relative bioavailability of simeprevir following single dose administration of age-appropriate... | 2015-09-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-005606-38 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Mode... | 2021-11-30 | bad-data |
| Reported results | 2015-000277-12 | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaquetype Psoriasis „Wieloośro... | 2016-03-11 | due-trials |
| Reported results | 2015-000288-16 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic ... | 2017-08-31 | due-trials |
| Reported results | 2015-000289-67 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarth... | 2017-09-26 | due-trials |
| Completed, but no date, and reported results | 2015-000459-25 | A Phase 2, 2-panel, Open-label, Randomized Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledi... | bad-data | |
| Reported results | 2015-000596-27 | A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola A... | 2018-01-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000735-32 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 2020-09-07 | bad-data |
| Reported results | 2015-000754-38 | A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination r... | 2020-09-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000946-41 | A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Jan... | 2020-02-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-000948-42 | A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ- 54861911 in Subjects who are Asymptomatic At Risk for Develop... | 2018-12-20 | bad-data |
| Trial is outside EEC, and reported results | 2015-001042-28 | Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children with ADHD (The ABC Study) | bad-data | |
| Trial is outside EEC, and reported results | 2015-001070-18 | The Effective and Tolerable Titration Scheme and Dosage in Children with Attention-deficit hyperactivity disorder Treated with OROS-Methylphenidate | bad-data | |
| Trial is outside EEC, and reported results | 2015-001081-26 | The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children with ADHD | bad-data | |
| Trial is outside EEC, and reported results | 2015-001084-39 | Efficacy and learning skill after OROS Methylphenidate treatment in adolescents with Attention-Deficit/Hyperactivity Disorder: A 12-week, multi-center, open-label study | bad-data | |
| Trial is outside EEC, and reported results | 2015-001216-35 | From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD | bad-data | |
| Trial is outside EEC, and reported results | 2015-001217-27 | An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children with ADHD (FOSCO) | bad-data | |
| Trial is outside EEC, and reported results | 2015-001218-92 | A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2015-001219-11 | A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-depen... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001220-31 | Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety | bad-data | |
| Trial is outside EEC, and reported results | 2015-001221-16 | A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia | bad-data | |
| Trial is outside EEC, and reported results | 2015-001222-42 | A double-blind trial comparing the efficacy, tolerability and safety of monotherapy topiramate versus phenytoin in subjects with seizures indicative of new onset epilepsy | bad-data | |
| Trial is outside EEC, and reported results | 2015-001223-23 | TOPAMAX (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX as Monotherapy in the Treatme... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001225-16 | An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Subjects 6 to 17 Years of age, Inclusive, With Cystic Fibrosis | bad-data | |
| Trial is outside EEC, and reported results | 2015-001226-42 | An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive | bad-data | |
| Trial is outside EEC, and reported results | 2015-001320-31 | A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents with Irritability Associated... | bad-data | |
| Reported results | 2015-001611-12 | A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy. Estudio ... | 2022-06-14 | due-trials |
| Reported results | 2015-001630-21 | Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism | 2018-08-24 | due-trials |
| Trial is outside EEC, and reported results | 2015-001653-32 | A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with inflammatory Bowel Disease | bad-data | |
| Reported results | 2015-001672-22 | A randomized, placebo-controlled, 2-way crossover, double-blind study to evaluate the efficacy, safety and tolerability of JNJ-42847922 in subjects with insomnia disorder without psychiatric comorbidi... | 2015-12-02 | due-trials |
| Exempt, with results | 2015-002003-28 | A Phase 1b, randomized, partially double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of multiple doses of orally administered JNJ-53718678 in infants hospi... | 2017-11-10 | not-yet-due |
| Reported results | 2015-002007-29 | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Disor... | 2019-02-04 | due-trials |
| Reported results | 2015-002610-76 | A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of ... | 2020-07-16 | due-trials |
| Other | 2015-002874-19 | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating... | not-yet-due | |
| Reported results | 2015-002923-24 | A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With ... | 2017-08-03 | due-trials |
| Reported results | 2015-002993-19 | An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Age... | 2018-08-02 | due-trials |
| Reported results | 2015-003002-17 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir Adult and Elderly Hospita... | 2017-03-15 | due-trials |
| Ongoing | 2015-003007-38 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therap... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2015-003578-34 | An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | 2022-12-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-004139-11 | A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Etude prospective internationale portant sur la tolérance clini... | 2022-02-25 | bad-data |
| Reported results | 2015-004200-38 | A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naïve a... | 2017-11-16 | due-trials |
| Reported results | 2015-004835-10 | A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Palip... | 2018-03-26 | due-trials |
| Reported results | 2015-005282-22 | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in... | 2019-01-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-000121-40 | A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric ... | 2020-10-06 | bad-data |
| Trial is partly outside EEC, and reported results | 2016-000259-28 | A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | 2021-06-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-000634-21 | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn¿... | 2022-01-24 | bad-data |
| Trial is outside EEC, and reported results | 2016-000728-24 | A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of S... | bad-data | |
| Trial is outside EEC, and reported results | 2016-000929-40 | A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma | bad-data | |
| Reported results | 2016-001163-37 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis incl... | 2019-11-18 | due-trials |
| Other | 2016-001205-16 | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma | not-yet-due | |
| Reported results | 2016-001224-63 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis | 2020-12-04 | due-trials |
| Reported results | 2016-001267-36 | PHARMACODYNAMIC EFFECTS OF NICOTINE MOUTH SPRAY AND CYTISINE TABLET. A STUDY IN HEALTHY SMOKERS. | 2016-10-07 | due-trials |
| Not reported Terminated | 2016-001641-79 | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administered ... | 2017-03-30 | due-trials |
| Reported results Terminated | 2016-001653-40 | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regim... | 2018-10-16 | due-trials |
| Other | 2016-001737-27 | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed ... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2016-001956-22 | A Randomized Double-blind Pharmacokinetic study of Ustekinumab in Pediatric Subjects with Moderately to Severely Active Crohn's Disease | 2022-03-18 | bad-data |
| Exempt | 2016-002017-22 | A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Adva... | not-yet-due | |
| Reported results | 2016-002022-37 | A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects wit... | 2018-02-06 | due-trials |
| Listed as ongoing, but also has a completion date | 2016-002057-38 | A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | 2023-08-16 | bad-data |
| Reported results | 2016-002095-26 | A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Sy... | 2020-04-23 | due-trials |
| Exempt | 2016-002122-36 | A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | not-yet-due | |
| Completed, but no date, and reported results | 2016-002135-15 | Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm® initial/ Fumaderm®) ... | bad-data | |
| Exempt, with results | 2016-002543-41 | An Open-label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Combination with Nivolumab Versus Nivolumab Monotherapy... | 2018-10-09 | not-yet-due |
| Exempt, with results | 2016-002579-83 | A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-... | 2019-09-26 | not-yet-due |
| Reported results | 2016-002608-19 | A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Vi... | 2018-01-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002918-43 | Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn¿s Disease Patients Treated with Ustekinumab Studio comparativo relativo alle strategie di mantenimento "treat to target"... | 2021-07-20 | bad-data |
| Reported results | 2016-002995-29 | A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis | 2018-09-20 | due-trials |
| Trial is outside EEC, and reported results | 2016-003016-12 | A study to assess the acceptability/swallowability of DRV-containing FDC tablets in HIV-1 infected adolescents, using matching placebo tablets. Rezolsta: EMEA-001280-PIP01-12-M01 Decision: P/0256/201... | bad-data | |
| Reported results | 2016-003328-22 | A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Sy... | 2021-10-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-003642-93 | A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of J... | 2022-04-18 | bad-data |
| Reported results | 2016-003990-17 | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms ... | 2018-12-18 | due-trials |
| Reported results | 2016-003992-23 | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms ... | 2019-04-11 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-004422-42 | A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive S... | 2023-03-31 | bad-data |
| Reported results | 2016-004550-15 | A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus ... | 2018-11-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-005223-88 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 years) with Type 2 Dia... | 2023-09-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000206-38 | A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Studio multicentrico, randomiz... | 2024-01-12 | bad-data |
| Exempt, with results | 2017-000225-12 | A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes | 2020-12-21 | not-yet-due |
| Trial is outside EEC, and reported results | 2017-000285-30 | Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected adults, adolescents and children aged 3 years and above. | bad-data | |
| Reported results | 2017-000613-22 | A 16 Week, Single-center, Randomized, Placebo- and Active-controlled Proof of Principle Study to Assess the Efficacy and Safety of a 5% Minoxidil Topical Gel Formulation in Male subjects with Androgen... | 2019-12-04 | due-trials |
| Reported results | 2017-000980-33 | A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects with Insomn... | 2022-04-27 | due-trials |
| Reported results | 2017-001110-29 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and i... | 2020-08-13 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-001345-27 | A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-seropositive Toddlers 12 to 24 Months of A... | 2020-04-21 | bad-data |
| Reported results | 2017-001489-53 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus | 2020-11-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-001696-22 | A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JN... | 2018-10-16 | bad-data |
| Reported results Terminated | 2017-001862-56 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ... | 2018-10-16 | due-trials |
| Reported results | 2017-001941-28 | A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation. | 2020-05-08 | due-trials |
| Exempt | 2017-001980-19 | A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects with Metastatic or Locally Advanced Urothelial Cancer | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2017-002156-84 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and ... | 2020-08-28 | bad-data |
| Ongoing | 2017-002195-13 | A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severel... | not-yet-due | |
| Reported results | 2017-002217-59 | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and... | 2020-08-28 | due-trials |
| Exempt | 2017-002400-26 | A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002611-34 | A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects wit... | 2021-11-19 | bad-data |
| Ongoing | 2017-002932-18 | A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations | not-yet-due | |
| Trial is partly outside EEC | 2017-003053-42 | A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Subcutaneously Administered Guselkumab for the Treatme... | bad-data | |
| Reported results | 2017-003194-33 | An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infecti... | 2018-11-27 | due-trials |
| Reported results | 2017-003252-24 | A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Level... | 2019-12-26 | due-trials |
| Ongoing | 2017-003364-12 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects wit... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2017-003377-34 | An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell or T... | 2022-09-22 | bad-data |
| Exempt | 2017-003552-23 | A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | not-yet-due | |
| Reported results | 2017-003616-39 | A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Seve... | 2019-03-08 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-003859-36 | A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age | 2021-11-02 | bad-data |
| Ongoing, reported early | 2017-004203-41 | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004209-41 | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderatel... | 2021-05-21 | bad-data |
| Ongoing | 2017-004496-31 | A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Part... | not-yet-due | |
| Other | 2017-004699-77 | A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia... | not-yet-due | |
| Ongoing | 2017-004958-42 | A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of ... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2018-000121-32 | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | bad-data | |
| Reported results | 2018-001176-38 | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | 2020-05-22 | due-trials |
| Ongoing | 2018-001238-16 | A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis | not-yet-due | |
| Reported results | 2018-001510-15 | A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Goli... | 2021-11-15 | due-trials |
| Other | 2018-001545-13 | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and... | not-yet-due | |
| Other | 2018-001746-34 | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002629-51 | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s ... | 2023-01-11 | bad-data |
| Reported results | 2018-003155-38 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis | 2023-02-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-003206-58 | A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | 2021-11-30 | bad-data |
| Reported results | 2018-003214-41 | Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis ... | 2020-11-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-003666-13 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 In... | 2023-08-10 | bad-data |
| Ongoing | 2018-004002-25 | A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul... | not-yet-due | |
| Other | 2018-004124-10 | A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004185-34 | A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multi... | 2022-10-17 | bad-data |
| Reported results | 2018-004229-10 | DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF PHARMACODYNAMIC EFFECTS OF 4 MG NICOTINE GUM. A STUDY IN HEALTHY SMOKERS WILLING TO QUIT Podwójnie zaślepione, z kontrolą placebo, badanie efektów farmakod... | 2019-09-26 | due-trials |
| Reported results | 2018-004237-32 | A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Sub... | 2021-04-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2018-004301-32 | A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 ... | 2023-02-17 | bad-data |
| Reported results | 2018-004532-30 | Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | 2022-04-27 | due-trials |
| Exempt | 2019-000330-19 | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma Estudio fase 1b de regímenes d... | not-yet-due | |
| Ongoing | 2019-000473-23 | A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-000622-22 | A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the T... | 2022-04-26 | bad-data |
| Trial is outside EEC, and reported results | 2019-000690-22 | A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebo... | bad-data | |
| Trial is outside EEC, and reported results | 2019-000691-42 | A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola | bad-data | |
| Reported results | 2019-000695-41 | A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects with Major... | 2020-05-06 | due-trials |
| Other | 2019-000720-17 | Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study | not-yet-due | |
| Reported results | 2019-001384-68 | A Study to Assess the Acceptability of Scored Film-coated darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Tablets in HIV-1 Infected Pediatric Particip... | 2020-03-06 | due-trials |
| Other | 2019-001413-16 | A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pom... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001509-25 | A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Stud... | 2021-05-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001551-39 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-5371867... | 2022-02-04 | bad-data |
| Other | 2019-001683-29 | Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious ... | not-yet-due | |
| Trial is partly outside EEC | 2019-002113-19 | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | bad-data | |
| Completed, but no date, and reported results Terminated | 2019-002245-37 | A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafen... | bad-data | |
| Ongoing | 2019-002449-39 | A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasiv... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-002674-31 | A Randomized, Double blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (NA) ... | 2022-06-09 | bad-data |
| Other | 2019-002957-46 | A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prost... | not-yet-due | |
| Reported results | 2019-002992-33 | A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Q... | 2022-09-26 | due-trials |
| Exempt, with results | 2019-003106-28 | A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lu... | not-yet-due | |
| Reported results Terminated | 2019-003335-37 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s Dise... | 2021-12-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-003576-40 | A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonoc... | 2022-05-05 | bad-data |
| Trial is partly outside EEC | 2019-004224-38 | A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pe... | bad-data | |
| Trial is partly outside EEC | 2019-004225-24 | A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in P... | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-004475-39 | A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JN... | 2024-01-09 | bad-data |
| Ongoing | 2019-004978-26 | A Phase 2, randomized, open-label, multicenter study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide anal... | not-yet-due | |
| Other | 2020-000116-30 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheim... | not-yet-due | |
| Ongoing | 2020-000337-40 | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderl... | not-yet-due | |
| Reported results | 2020-000338-16 | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderl... | 2022-07-14 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-000341-14 | A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adu... | 2023-10-03 | bad-data |
| Ongoing | 2020-000622-26 | A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis | not-yet-due | |
| Other | 2020-000633-40 | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or... | not-yet-due | |
| Exempt | 2020-000657-27 | A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in... | 2022-02-23 | not-yet-due |
| Other | 2020-000743-31 | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic ... | not-yet-due | |
| Ongoing | 2020-001249-37 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)ide Anal... | not-yet-due | |
| Exempt, with results | 2020-001483-28 | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years... | 2023-03-03 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2020-002023-11 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (>or=28 Days to <or=5 Years of Age) and Subsequently in Neonate... | 2022-04-18 | bad-data |
| Other | 2020-002209-25 | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Particip... | not-yet-due | |
| Trial is partly outside EEC | 2020-002255-37 | Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. Studio di follow-up di fase 3 di AAV5-... | bad-data | |
| Trial is partly outside EEC, and reported results | 2020-002584-63 | A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Age... | 2022-03-09 | bad-data |
| Reported results | 2020-002587-31 | A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants wi... | 2022-03-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-002607-19 | A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of... | 2022-11-23 | bad-data |
| Ongoing | 2020-002620-36 | A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (M... | not-yet-due | |
| Ongoing | 2020-002646-16 | Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2020-002701-26 | A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Concept Clinical Study to Evaluate the Safety and Efficacy of JNJ-64304500 as Add-on Therapy to Standard ... | bad-data | |
| Trial is partly outside EEC | 2020-002873-88 | Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene | bad-data | |
| Reported results | 2020-003396-18 | A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Adult Participants to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofo... | 2021-07-02 | due-trials |
| Reported results | 2020-003397-43 | A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 675 mg in the Presence of 150 mg Cobicistat When Adminis... | 2021-03-01 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-003643-29 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older | 2023-06-18 | bad-data |
| Ongoing | 2020-003698-24 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects with Focal Onset ... | not-yet-due | |
| Completed, report not yet due | 2020-003956-34 | A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated I... | 2023-04-17 | not-yet-due |
| Completed, report not yet due | 2020-004061-39 | A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis | 2023-07-28 | not-yet-due |
| Ongoing | 2020-004291-18 | Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013 | not-yet-due | |
| Trial is partly outside EEC | 2020-004431-24 | Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus ... | bad-data | |
| Other | 2020-004457-76 | A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age) | not-yet-due | |
| Other | 2020-004506-64 | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants wi... | not-yet-due | |
| Ongoing | 2020-004742-11 | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexametha... | not-yet-due | |
| Ongoing | 2020-004981-20 | A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibit... | not-yet-due | |
| Ongoing | 2020-005273-27 | Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Path... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2020-005330-14 | An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants. Estudio en fase II, abierto para evaluar la seguridad, la re... | bad-data | |
| Completed, reported early Terminated | 2020-005458-97 | A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and O... | 2023-07-21 | not-yet-due |
| Trial is partly outside EEC | 2020-005503-40 | A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab in Pediatric Participants With Active Juvenile... | bad-data | |
| Ongoing | 2020-005521-84 | Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel | not-yet-due | |
| Ongoing | 2020-005565-13 | A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Sc... | not-yet-due | |
| Ongoing | 2020-005568-79 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nipocalimab in Adult Participants with Active Lupus Nephritis Um estudo de fase 2, multicêntrico, aleatorizado, de dupl... | not-yet-due | |
| Ongoing | 2020-005569-14 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-005720-11 | A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Ado... | bad-data | |
| Other | 2020-005732-29 | Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized... | not-yet-due | |
| Completed, reported early | 2020-005801-14 | A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults | 2023-07-10 | not-yet-due |
| Reported results Terminated | 2020-005900-21 | A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab for ... | 2022-03-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-005980-30 | A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection wh... | 2022-04-14 | bad-data |
| Ongoing | 2020-006165-11 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to S... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-000189-13 | SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes | bad-data | |
| Ongoing | 2021-000202-22 | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom... | not-yet-due | |
| Ongoing | 2021-000465-32 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic ... | not-yet-due | |
| Ongoing | 2021-000482-32 | A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis... | not-yet-due | |
| Ongoing | 2021-000491-10 | A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Studio mult... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-000510-42 | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants with Ac... | 2022-08-10 | bad-data |
| Trial is partly outside EEC | 2021-000567-77 | A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an ... | bad-data | |
| Listed as ongoing, but also has a completion date | 2021-000665-32 | A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | 2023-11-30 | bad-data |
| Trial is partly outside EEC, and reported results | 2021-000738-32 | A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged ≥3 Years and Weighing ≥15 ... | bad-data | |
| Ongoing | 2021-001242-35 | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA ve... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-001331-10 | A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and Sier... | bad-data | |
| Other | 2021-001825-33 | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Ad... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-001909-77 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59Years, Including Those at High-risk for ... | 2022-08-12 | bad-data |
| Ongoing | 2021-002012-31 | A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psori... | not-yet-due | |
| Reported results | 2021-002450-81 | A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Pati... | 2021-12-29 | due-trials |
| Trial is partly outside EEC | 2021-002479-20 | An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to less than 18 years with Generalized Myasthenia... | bad-data | |
| Other | 2021-002639-48 | A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis | not-yet-due | |
| Ongoing | 2021-003234-37 | Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic ... | not-yet-due | |
| Ongoing | 2021-003314-39 | A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkum... | not-yet-due | |
| Ongoing, reported early | 2021-003700-41 | A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis Estudio en fa... | not-yet-due | |
| Reported results | 2021-003953-43 | A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older | 2022-11-15 | due-trials |
| Reported results | 2021-003955-40 | A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 600 mg in the Presence of Cobicistat 90 mg When Administ... | 2022-09-28 | due-trials |
| Listed as ongoing, but also has a completion date | 2021-004320-16 | A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | 2023-09-29 | bad-data |
| Ongoing | 2021-004790-31 | A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression | not-yet-due | |
| Ongoing | 2021-005132-33 | A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Patient... | not-yet-due | |
| Other | 2021-005202-98 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopat... | not-yet-due | |
| Ongoing | 2021-005528-39 | A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkum... | not-yet-due | |
| Ongoing | 2021-005987-23 | A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderat... | not-yet-due | |
| Trial is partly outside EEC | 2021-006282-37 | A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease Efficacia, sicurezza e farmacocinetica di guselkumab in ... | bad-data | |
| Other | 2021-006629-23 | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | not-yet-due | |
| Ongoing | 2022-000364-21 | A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezo... | not-yet-due | |
| Ongoing | 2022-000365-41 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderat... | not-yet-due | |
| Exempt | 2022-000380-46 | A Phase I/Ib Study of JNJ-75276617 in Combination with Conventional Chemotherapy for Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleopor... | not-yet-due | |
| Ongoing | 2022-000430-42 | An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) | not-yet-due | |
| Ongoing | 2022-000439-22 | A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants wit... | not-yet-due | |
| Ongoing | 2022-000461-41 | A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants wit... | not-yet-due | |
| Exempt | 2022-000485-18 | A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (Investigation-specific Appendix 1 to Maste... | not-yet-due | |
| Ongoing | 2022-000525-25 | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery... | not-yet-due | |
| Ongoing | 2022-000526-21 | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. ... | not-yet-due | |
| Ongoing | 2022-000909-28 | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratu... | not-yet-due | |
| Ongoing | 2022-000928-37 | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multipl... | not-yet-due | |
| Ongoing | 2022-000974-25 | Evaluation of Amivantamab Infusion Related Reaction Mitigation Evaluación de la Mitigación de las Reacciones Relacionadas con la Infusión de Amivantamab. | not-yet-due | |
| Exempt, with results Terminated | 2022-001015-14 | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older Estudio en... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2022-001442-38 | A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma who have Received at least 4 Prior Therapies Including an Immunomodulatory Drug,... | 2022-11-16 | bad-data |
| Ongoing | 2022-001528-14 | A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-67484703 in Participants with Atopic Dermatitis | not-yet-due | |
| Completed, report not yet due Terminated | 2022-002389-33 | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn's Disease After Surgical Resection Studio randomiz... | 2023-10-10 | not-yet-due |
| Trial is outside EEC | 2023-000984-30 | A Multicenter, Open-label, Phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients (≥3 months to <15 years) with Pulmonary Arterial Hypertensi... | bad-data |